证券代码：603102 证券简称：百合股份 公告编号：2025-010 威海百合生物技术股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日 向各位监事发出了召开第四届监事会第十次会议的通知。2025 年 4 月 14 日，第 四届监事会第十次会议以现场投票的表决方式在公司会议室召开，应出席本次会 议的监事 3 人，实际出席本次会议的监事 3 人。本次会议由监事会主席召集和主 持，会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的有关规定。 二、监事会会议审议情况 与会监事经认真审议和表决，通过如下决议： （一）审议通过了《关于公司 2024 年度监事会工作报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 本议案需提交公司股东大会审议。 （二）审议通过了《关于公司 2024 年年度报告及其摘要的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 ...

一、董事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日 向各位董事发出了召开第四届董事会第十一次会议通知。2025 年 4 月 14 日，第 四届董事会第十一次会议以通讯和现场投票相结合表决方式在公司会议室召开， 应出席本次会议的董事 9 人，实际出席本次会议的董事 9 人，公司相关高级管理 人员列席了本次会议。本次会议由董事长刘新力召集和主持，会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事经认真审议和表决，通过如下决议： 证券代码：603102 证券简称：百合股份 公告编号：2025-009 威海百合生物技术股份有限公司 第四届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）审议通过了《关于公司 2024 年度总经理工作报告议案》 表决结果：9 票同意，0 票反对，0 票弃权。 （二）审议通过了《关于公司 2024 年度董事会工作报告的议案》 表决结果：9 票同意，0 票反 ...

Dividend Distribution - The company plans to distribute a cash dividend of 7.50 RMB per 10 shares, totaling approximately 47,165,400 RMB (including tax) based on a total share count of 62,887,200 shares after buybacks[7]. - The total cash dividend amount for 2024, including share buybacks, is 47,771,488 RMB (including tax), representing 34.29% of the net profit attributable to shareholders[8]. - The profit distribution proposal is subject to approval at the shareholders' meeting[9]. - The cash dividend amount represents 33.86% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which is 139,309,114.98 RMB[156]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) is 132,800,100 RMB, with an average cash dividend ratio of 89.28%[158]. Financial Performance - The company's operating revenue for 2024 was CNY 801,399,192.56, a decrease of 8.02% compared to CNY 871,251,536.54 in 2023[29]. - The net profit attributable to shareholders for 2024 was CNY 139,309,114.98, down 17.60% from CNY 169,065,646.64 in 2023[29]. - The net cash flow from operating activities decreased by 34.15% to CNY 127,647,807.89 in 2024 from CNY 193,851,041.12 in 2023[29]. - The total assets at the end of 2024 were CNY 1,815,740,918.83, reflecting a 4.58% increase from CNY 1,736,159,386.58 at the end of 2023[29]. - The net assets attributable to shareholders increased by 6.04% to CNY 1,605,932,193.78 at the end of 2024 from CNY 1,514,464,171.80 at the end of 2023[29]. - Basic earnings per share for 2024 were CNY 2.18, a decrease of 17.42% compared to CNY 2.64 in 2023[30]. - The weighted average return on equity for 2024 was 8.95%, down 2.44 percentage points from 11.39% in 2023[30]. - The company achieved a total revenue of 801,399,192.56 CNY in the reporting period, representing a year-on-year decline of 8.02%[79]. - The net profit attributable to shareholders was 13,930.55 million CNY, down 17.60% compared to the previous year[79]. Audit and Compliance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[6]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The internal control system has been effectively maintained in all significant aspects of financial and non-financial reporting[161]. - The company has not disclosed any significant internal control deficiencies during the reporting period[161]. - The company has appointed Rongcheng Accounting Firm for auditing services with a fee of RMB 900,000 for the current year[198]. - The internal control audit will also be conducted by Rongcheng Accounting Firm with a fee of RMB 300,000[200]. - There are no significant lawsuits or arbitration matters reported for the current fiscal year[200]. - The company has not faced any delisting risks or bankruptcy restructuring issues during the reporting period[200]. Research and Development - Research and development expenditure reached 35.78 million yuan, with an R&D investment ratio of 4.47%, an increase of 15.63% compared to the previous year[40]. - The company has developed a robust R&D system, focusing on market responsiveness and technological innovation, to capture diverse consumer health needs[66]. - The number of R&D personnel is 152, accounting for 13.26% of the total workforce[92]. - The company is committed to continuous talent development and innovation, enhancing the professional level of its R&D team through various training programs[68]. - The company launched innovative products such as dandelion and chrysanthemum nutrition jelly, combining traditional herbal formulas with modern nutrition science[76]. Market Strategy and Expansion - The company aims to deepen its international strategy and expand into the pet nutrition sector, creating a comprehensive product matrix covering both human and companion animal health[117]. - The company plans to develop high-bioavailability functional pet dietary supplements to fill the gap in the domestic precise nutrition market for pets[117]. - The company is strategically expanding into the pet nutrition market, developing high-quality pet nutritional supplements[77]. - The company plans to develop a customized product line targeting the rapidly growing female health market, including collagen peptide oral liquids and weight management meal replacements[45]. - The company aims to establish a tiered service system for brand clients, including integrated services for top 10 strategic clients, modular solutions for small and medium-sized clients, and cross-border solutions for emerging clients[44]. Risk Management - The company has outlined potential risks in the management discussion and analysis section of the report[13]. - The company faces risks related to product quality and food safety, which could impact its reputation and sales if quality management errors occur[120]. - Regulatory changes in the nutrition and health food industry may significantly affect the company's long-term development and competitive landscape[121]. - The company is experiencing a shift towards digital and compliant operational models in response to regulatory pressures, enhancing its marketing strategies[115]. Corporate Governance - The company has established specialized committees, including the Audit Committee and the Strategic Committee, to enhance governance[143]. - The company has appointed new independent directors, which will strengthen its governance structure[134]. - The company will continue to evaluate the independence of its independent directors[144]. - Total remuneration for all directors, supervisors, and senior management amounted to CNY 754.02 million[138]. - The company held four board meetings during the year, all conducted via communication methods[142]. Environmental Responsibility - The company has not established an environmental protection mechanism and did not invest in environmental protection funds during the reporting period[164]. - The company did not implement any carbon reduction measures during the reporting period[167]. - There were no disclosures related to environmental responsibility or sustainability reports[165]. Shareholder Commitments - The company has commitments regarding share transfer restrictions for major shareholders for 36 months post-IPO[169]. - Major shareholders are restricted from transferring shares for 12 months post-IPO[172]. - The company has a plan to potentially reduce shares after the lock-up period, with a maximum of 100% of shares held at the time of listing[173]. - The controlling shareholder has pledged to avoid any business activities that may compete with the company's operations[177]. - The company will ensure that all directors and senior management are jointly responsible for the accuracy and completeness of the IPO prospectus[182].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 207,021,839.55, representing a 9.75% increase compared to CNY 188,638,808.65 in the same period last year[4]. - The net profit attributable to shareholders was CNY 35,205,793.15, a slight increase of 1.02% from CNY 34,850,457.04 year-on-year[4]. - Total operating revenue for Q1 2025 reached ¥207,021,839.55, an increase of 9.3% compared to ¥188,638,808.65 in Q1 2024[16]. - Operating profit for Q1 2025 was ¥40,460,562.58, slightly higher than ¥39,864,164.04 in Q1 2024, reflecting a growth of 1.5%[16]. - The net profit for Q1 2025 was CNY 35,205,793.15, an increase of 1.01% compared to CNY 34,850,457.04 in Q1 2024[17]. - The net profit for Q1 2025 was ¥35,464,740.40, up from ¥34,789,960.43 in Q1 2024, indicating a growth of 1.9%[28]. Cash Flow - The net cash flow from operating activities surged by 94.32%, reaching CNY 52,023,678.44, primarily due to increased sales collections[7]. - The operating cash flow for Q1 2025 was CNY 52,023,678.44, significantly up from CNY 26,771,614.42 in Q1 2024, representing a growth of 94.5%[19]. - The net cash flow from operating activities for Q1 2025 was ¥50,571,095.45, compared to ¥26,670,620.17 in Q1 2024, showing a significant increase of 89.6%[30]. - The company reported a net cash outflow from investing activities of CNY -68,191,702.46 in Q1 2025, compared to CNY -71,233,328.18 in Q1 2024[20]. - The company received cash inflows from investment activities amounting to ¥3,855,700.23 in Q1 2025, compared to ¥3,499,858.64 in Q1 2024[30]. Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 1,849,994,805.46, reflecting a 1.89% increase from CNY 1,815,740,918.83 at the end of the previous year[5]. - Total assets as of March 31, 2025, were ¥1,849,994,805.46, compared to ¥1,815,740,918.83 at the end of 2024, indicating a growth of 1.9%[14]. - Total liabilities as of March 31, 2025, were ¥212,076,285.53, a slight increase from ¥209,808,725.05 at the end of 2024[14]. - The total liabilities increased to ¥210,495,459.98 from ¥208,238,785.02, reflecting a rise of 1.1%[26]. Shareholder Information - The equity attributable to shareholders increased by 1.99% to CNY 1,637,918,519.93 from CNY 1,605,932,193.78[5]. - The total equity attributable to shareholders as of March 31, 2025, was ¥1,637,918,519.93, an increase of 2.0% from ¥1,605,932,193.78 at the end of 2024[14]. - The total number of ordinary shareholders at the end of the reporting period was 8,115[9]. - The largest shareholder, Liu Xinli, holds 40.94% of the shares, totaling 26,198,803 shares[9]. Earnings and Expenses - Basic earnings per share for the period were CNY 0.55, up 1.85% from CNY 0.54 in the previous year[4]. - The basic and diluted earnings per share for Q1 2025 were both CNY 0.55, up from CNY 0.54 in Q1 2024[17]. - Research and development expenses for Q1 2025 were ¥6,748,357.14, a decrease of 8.6% compared to ¥7,382,842.54 in Q1 2024[16]. - Research and development expenses for Q1 2025 were ¥6,692,025.42, a decrease of 9.3% from ¥7,382,842.54 in Q1 2024[27]. - The company reported a decrease in financial expenses, with a net financial income of -¥3,667,314.66 in Q1 2025 compared to -¥3,508,047.42 in Q1 2024[27]. Government Support - The company received government subsidies amounting to CNY 65,900.00, which are closely related to its normal business operations[6].

证券代码：603102 证券简称：百合股份 公告编号：2025-015 威海百合生物技术股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每 10 股分配比例：拟每 10 股派发现金股利 7.50 元（含税）。 ● 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 ● 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 ● 公司不存在触及《上海证券交易所股票上市规则》（以下简称"《股票 上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的 情形。 一、利润分配预案内容 （一）利润分配预案的具体内容 经容诚会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，母 公司可供分配利润为 821,843,519.02 元。经公司第四届董事会第十一次会议决议， 公司 2024 年度拟以权益分派股权登记日登记 ...

百合股份（603102）公告，2024年营业收入8.01亿元，同比下降8.02%。归属于上市公司股东的净利润 1.39亿元，同比下降17.60%。公司拟向全体股东每10股派发现金红利7.5元(含税)。以6288.72万股为基 数，合计拟派发现金红利4716.54万元(含税)。 ...

Core Insights - The company reported a revenue of 207 million yuan for the first quarter of 2025, representing a year-on-year growth of 9.75% [1] - The net profit for the same period was 35.21 million yuan, showing a slight increase of 1.02% year-on-year [1] Financial Performance - Revenue: 207 million yuan, up 9.75% year-on-year [1] - Net Profit: 35.21 million yuan, up 1.02% year-on-year [1]

证券代码：603102 证券简称：百合股份 公告编号：2025-008 威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/9 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 8 月 日~2025 年 月 7 | 日 | 8 | 8 | | 预计回购金额 | 万元 3,000 万元~6,000 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 92,400 股 | | | | | 累计已回购股数占总股本比 | 0.14% | | | | | 例 | | | | | | 累计已回购金额 | 3,218,092 元 | | | | | 实际回购价格区间 | 34.64 元/股~35.00 元 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-007 威海百合生物技术股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司首次回购股份的情况公告如下： 2025 年 3 月 10 日，公司通过上海证券交易所系统以集中竞价交易方式首次回 购公司 A 股普通股股票 92,400 股，占公司当前总股本的比例为 0.14%，回购的最 高成交价格为人民币 35.00 元/股，最低成交价格为人民币 34.64 元/股, 支付的资金 总额为人民币 3,218,092 元（不含印花税、交易佣金等交易费用）。 本次回购股份符合相关法律法规的规定及公司回购股份方案的要求。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予 ...

证券代码：603102 证券简称：百合股份 公告编号：2025- 006 威海百合生物技术股份有限公司 关于变更签字注册会计师及项目质量复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 威海百合生物技术股份有限公司（以下称"公司"）于 2024 年 4 月 11 日召 开第四届董事会第七次会议和第四届监事会第六次会议，审议通过《关于续聘公 司 2024 年度审计机构的议案》，拟续聘容诚会计师事务所（特殊普通合伙）（以 下简称"容诚会计师事务所"）为公司 2024 年度审计机构，该事项已于 2024 年 5 月 8 日经公司 2023 年年度股东大会审议通过。具体内容详见公司于 2024 年 4 月 12 日披露的《关于续聘会计师事务所的公告》（公告编号：2024-012）和 2024 年 5 月 9 日披露的《2023 年年度股东大会决议公告》（公告编号：2024-015）。 近日，公司收到容诚会计师事务所出具的《关于变更签字注册会计师及项目 质量复核人的说明函》，现将相关情况公告如下： 一、 签字注册会计师及项目 ...